Paragraph IV Challenges
✉ Email this page to a colleague
Tradename | Dosage | Generic Name | NDA | ANDAs Submitted | 180 Day Exclusivity Status | Submissiondate |
---|---|---|---|---|---|---|
REYVOW | Tablets | lasmiditan succinate | 211280 | 1 | 2024-01-31 | |
MYRBETRIQ GRANULES | Granules for Extended-release Suspension | mirabegron | 213801 | 1 | 2024-01-12 | |
ATROVENT HFA | Inhalation Aerosol | ipratropium bromide | 021527 | 1 | 2023-12-29 | |
>Tradename | >Dosage | >Generic Name | >NDA | >ANDAs Submitted | >180 Day Exclusivity Status | >Submissiondate |